TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
08 mars 2023 07h00 HE
|
TScan Therapeutics, Inc.
Phase 1 umbrella trial for TSC-100 and TSC-101 in hematologic malignancies on track to enroll patients into each of the three study arms and provide a clinical update including safety and biomarker...
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
01 mars 2023 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
21 févr. 2023 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
23 janv. 2023 07h00 HE
|
TScan Therapeutics, Inc.
Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies based on target and HLA expression INDs for...
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
05 janv. 2023 07h00 HE
|
TScan Therapeutics, Inc.
Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 Advancing solid tumor program with development...
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
12 déc. 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
01 déc. 2022 08h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference
22 nov. 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting
11 nov. 2022 07h00 HE
|
TScan Therapeutics, Inc.
TCRs for an HLA-A*02:01 epitope of PRAME now in IND-enabling studies Multiplexing TCRs for MAGE-A1 and PRAME demonstrates synergistic cytotoxicity in vitro and in mouse xenograft models Company...
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
09 nov. 2022 07h00 HE
|
TScan Therapeutics, Inc.
Four sites for hematologic malignancies program open and enrolling patients Completed pre-IND meeting with the FDA for solid tumor program; virtual investor event Monday, November 14, at 5:00 PM ET...